Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b trial evaluating Etakafusp Alfa in combination with IMDELLTRA® (tarlatamab)

Next Previous
X
Search
Trial Profile

Phase 1b trial evaluating Etakafusp Alfa in combination with IMDELLTRA® (tarlatamab)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etakafusp alfa (Primary) ; Tarlatamab (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Amgen

    • Most Recent Events

    • 14 Jan 2025 New trial record
    • 08 Jan 2025 According to Asher Bio Media release, This clinical trial collaboration and supply agreement with Amgen allows us to further expand on the Phase 1 results for etakafusp alfa in a new combination with IMDELLTRA in a global Phase 1b study in ES-SCLC.
    • 08 Jan 2025 According to Asher Bio Media release, company announced a clinical trial collaboration and supply agreement with Amgen (NASDAQ:AMGN) to evaluate etakafusp alfa in combination with tarlatamab in patients with extensive-stage small cell lung cancer (ES-SCLC).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top